The Amyotrophic Lateral Sclerosis Association and SOLA Biosciences entered a Research Grant Agreement to advance ALS animal efficacy studies of SOL-257.

Series Pre-A Financing completed with MP Healthcare Venture Management Inc. and Eisai Innovation Inc.

SOL-257, an experimental gene therapy developed by SOLA Biosciences, has shown encouraging preclinical results by slowing disease progression and significantly extending survival in a mouse model of amyotrophic lateral sclerosis (ALS) through targeting toxic, misfolded TDP-43 protein that drives neuronal damage. The therapy, presented at a major neuromuscular disease research